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Influence of flavonoids’ lipophilicity on platelet aggregation
Flavonoids are natural polyphenolic compounds present in a 
wide spectrum of plants that have a beneficial effect on human 
health. In the context of cardiovascular diseases related to 
plaque and thrombus formation, flavonoids exhibit an anti-
aggregatory effect. Previously, it has been reported that all tested 
flavonoids exhibit an antiaggregatory effect on platelet aggrega-
tion when measured by impedance aggregometry on whole 
blood, in the test of aggregation induced by adenosine diphos-
phate (ADP). As not all flavonoids have the same targets within 
signaling pathways, an assumption of a common non-specific 
mechanism related to lipophilicity is to be considered. To test 
this hypothesis, reverse-phase thin layer chromatography was 
used to assess the lipophilicity of flavonoids; impedance ag-
gregometry was used for testing of platelet aggregation and 
flow cytometry to monitor the influence of flavonoids on plate-
let activation. Lipophilicity analysis showed a highly negative 
correlation of logP and MINaAC for groups of flavones and fla-
vanones. As determined by flow cytometry, the exposition of 
receptors necessary for the promotion of platelet activation and 
primary clot formation was diminished, i.e., lowered expres-
sion of the activated form of integrin αIIbβ3 was observed in 
the presence of flavanone. Platelet membrane stabilization by 
flavonoids as a mechanism of antiaggregatory effect has been 
supported by impedance aggregometry experiments when spe-
cific inhibitors of platelet aggregation signaling pathways 
(U73122, indomethacin, verapamil) were used in the presence 
of a weak (ADP) and a strong (TRAP-6) agonist of aggregation. 
While individual flavonoids can have specific targets within ag-
gregation signaling pathways, all flavonoids share a common 
non-specific mechanism of platelet aggregation inhibition re-
lated to their lipophilicity and membrane stabilization that, to 
some extent, contributes to their antiaggregatory effect.
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Flavonoids are natural polyphenolic compounds present in a wide spectrum of plants. 
One of the prominent and well documented beneficial effects on human health that has 
been confirmed in epidemiological studies is known as French paradox, i.e., although 
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French population consumes fat-rich diet, incidence of cardiovascular diseases is lower 
than expected as their diet is also rich in polyphenols (1, 2). Based on their accessibility to 
humans through the dietary intake of fruits, vegetables and some beverages, flavonoids 
have been a topic of research for many years including their possible use as lead com-
pounds for novel pharmaceutical agents. Many in vitro studies on plant and fruit extracts 
or on pure flavonoid compounds confirm antithrombotic, especially antiplatelet, effect in 
dose depending manner although without revealing the mechanism of action (3–5). In 
regard to cardiovascular diseases related to plaque and thrombus formation, flavonoids 
exhibit the antiaggregatory effect. For some flavonoids, this is attributed to the inhibition 
of cyclooxygenase, lipoxygenase, tyrosine-kinase, phosphodiesterase or phospholipase 
which participate in platelet signaling pathway (6–8).
Lipophilicity of flavonoids has been a subject of studies exploring flavonoid-membrane 
interactions. According to the results presented in previous studies, flavonoids are positioned 
within the membrane depending on their polarity, with more hydrophobic ones which pene-
trate deeper in the core of membrane bilayer, interact with membrane transporter proteins, 
and decrease membrane fluidity (9, 10). Platelet membrane is the best example of membrane 
fluidity; it functions as a dynamic structure involved in processes of activation and aggrega-
tion. These processes depend strongly on phospholipid transverse distribution in resting and 
activated state, and processes in the inner leaflet of platelet membrane (11).
Work of Lipinski et al. (12) represents the milestone for determination of the relation-
ship between pharmacokinetic and physicochemical parameters by establishing “rule-of-
five” and uses logP as a measure of the compound’s lipophilicity. Partition coefficient (P) 
represents a ratio between the concentration of the non-ionized form of the compound in 
the n-octanol-water system expressed in logarithmic scale (logP). While the shake-flask 
method is the gold standard for logP determination, lipophilicity is nowadays more often 
determined indirectly by liquid chromatography (13). The simple approach is the determi-
nation by planar chromatography that uses chromatographic parameter RM (parameter 
calculated based on the retention factor of substance) as a surrogate measurement of lipo-
philicity. To bypass laborious and time-consuming experimental methods, several com-
putational approaches for the prediction of lipophilicity (logP) have been developed based 
on pool of predefined atoms, fragments and their contribution factors (14–16).
In the previous work by Bojić et al. (17) it has been shown that all tested flavonoids, 
without exception, exhibit the antiaggregatory effect on platelet aggregation induced by 
adenosine diphosphate (ADP). As not all flavonoids have the same targets within signaling 
pathways, an assumption of a common non-specific mechanism related to lipophilicity is to 
be considered. Thus, the aim of this study was to examine the flavonoids antiaggregatory 




Blood samples were collected at Croatian Institute of Transfusion Medicine (Zagreb, 
Croatia) in 4.5-mL vacutainer tubes with tri-sodium citrate (3.8 %) as an anticoagulant. 
Fifty blood donors who were not on any antiaggregatory therapy gave written, informed 
consents before participating in research. The study was conducted according to Helsinki 
declaration and with approval of Ethics Committee of the Croatian Institute of Transfusion 
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Medicine and the University of Zagreb Faculty of Pharmacy and Biochemistry. All mea-
surements were conducted in two hours after the blood sample collection.
Reagents
Flavonoid aglycons used in this work are listed in Table I. Flavonoid solutions were 
prepared by dissolving standards in methanol (Kemig, Croatia) for the purpose of thin-
layer chromatography analysis, while serial of doubling dilutions (1/2n) in dimethyl sulf-
oxide (DMSO, Merck KgaA, Germany) in the concentration range of 500 mmol L–1 to 62 
nmol L–1 was used for platelet aggregation analysis. ADP, collagen, TRAP-6, arachidonic 
acid (AA) and ristocetin were obtained from Roche Diagnostics (Germany), and saline (0.9 
% NaCl) with and without calcium chloride from the Croatian Institute of Transfusion 
Medicine. Inhibitor of cyclooxygenase, indomethacin, and calcium channels blocker, vera-
pamil hydrochloride, were purchased from Acros Organics (Thermo Fisher Scientific, Bel-
gium) and inhibitor of phospholipase C (PLC), U73122 from Merck KgaA. Anti-integrin 
αIIbβ3 antibody (PAC-1) labelled with fluorescein isothiocyanate (FITC), anti-CD61 la-
belled with phycoerythrin (PE), FITC mouse IgM, κ isotype control and PE mouse IgG1, κ 
isotype control for flow cytometry experiments were purchased from Becton Dickinson 
(USA). Reverse-phase thin-layer chromatography was performed on Merck RP-18 F254S 
plates with a mobile phase consisting of water, acetonitrile and glacial acetic acid (last two 
solvents were obtained from Kemig, Croatia, while distilled water was prepared in house).
Reverse-phase thin-layer chromatography and computational determination of lipophilicity
Twenty flavonoid compounds were analyzed by reverse-phase thin-layer chromatog-
raphy (RP-TLC) using acetonitrile/water/glacial acetic acid in a ratio 66:33:1 (V/V/V) as a 
mobile phase. After development, flavonoids were detected as dark spots on a chromato-
graphic plate with the fluorescent indicator (wavelength 254 nm). Based on retention factor, 
RF, chromatographic parameter RM was calculated as follows RM = log [(1/RF) – 1].
Calculation of theoretical logP was performed using online applications Chemicalize 
(https://chemicalize.com), ChemSketch (http://www.chemspider.com), Molinspiration 
(https://www.molinspiration.com) and SwissADME (http://www.swissadme.ch). Swis-
sADME is calculating logP in five different ways and expresses their consensus logP value. 
Values of experimentally determined chromatographic parameter RM were correlated with 
calculated logP values using MS Office Excel (Microsoft, USA) and reported as correlation 
coefficient and adjusted squared correlation coefficient at a significance level of p < 0.05.
Impedance aggregometry
Impedance aggregometry on whole blood was monitored on Multiplate® instrument 
(Roche Diagnostics, Germany) and was used for determination of minimum antiaggregatory 
concentration (MINaAC) of flavanone in the presence of a set of agonists (TRAP-6, ADP, col-
lagen, AA, ristocetin) by previously described method (17). Briefly, the influence of serial 
doubling concentrations of flavanone on platelet aggregation was measured by using original 
Multiplate procedure as follows: 300 μL of blood was incubated for 3 minutes at 37 °C with 20 
μL flavonoid and 300 μL of saline-CaCl2 preheated at 37 °C. Vehicle – DMSO (final concentra-
tion 3 %) was used as a negative control (untreated sample). Aggregation was induced by 
addition of 20 μL of the agonist with final concentrations: 6.3 μmol L–1 ADP, 3.1 μg mL–1 
 collagen, 31 μmol L–1 TRAP-6, 0.48 μmol L–1 AA, and 0.3 mg mL–1 ristocetin. MINaAC was 
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determined in three independent measurements for treated and untreated sample using the 
Student’s t-test. The same pre-defined Multiplate protocol was followed for the assessment of 
the combined effect of inhibitory drugs (U73122 hydrate, verapamil hydrochloride, indo-
methacin) and flavanone. Measurements were conducted with TRAP-6 as a strong and ADP 
as a weak agonist using 15 and 60 x MINaAC of flavanone to ensure repeatable inhibition 
effect on platelet aggregation. U73122 hydrate, verapamil hydrochloride, and indomethacin were 
used in concentrations previously reported in the literature (18–20), i.e., 4 μmol L–1 U73122, 
82.5 μmol L–1 verapamil and 0.21 μmol L–1 indomethacin in platelet aggregation test induced 
with 30 μmol L–1 TRAP-6, while in platelet aggregation test induced with 6.3 μmol L–1 ADP 
concentrations were for U73122, verapamil and indomethacin 3.2 μmol L–1, 52 μmol L–1 and 
0.21 μmol L–1, resp. Results of aggregation for untreated sample (DMSO, 0.8 %), flavanone treated, 
inhibitor drug-treated, and for the sample treated with the combination of flavanone and in-
hibitor drug were statistically assessed using ANOVA.
Flow cytometry
Platelet-rich plasma (PRP) was obtained by centrifugation of freshly drawn citrate 
blood samples at 150 g for 10 min. Platelet concentration was adjusted to 20.000 per μL with 
phosphate-buffered saline (pH 7.4). One mL of PRP was pre-incubated with three dilutions 
of flavanone (30, 244 and 488 μmol L–1) or with the vehicle as a control (DMSO, 0.8 %) for 
15 minutes at 37 °C. An aliquot of 72 μL treated sample (flavanone, DMSO) was mixed with 
agonist TRAP-6 (final concentration 21 μmol L–1) and the excess amount of anti-CD61 (PE) 
to mark platelet population and PAC-1 FITC to monitor the activated form of integrin 
αIIbβ3. The sample was incubated in the dark at 37 °C, for 30 min. Flow cytometry runs 
were performed on FC500, Beckman Coulter (France). To distinguish platelet cell popula-
tion based on cell size and granularity, forward vs. side scatter was used collecting 10.000 
CD61 positive events. Isotype controls FITC labelled mouse IgM κ, and IgG1 PE were used 
to monitor the level of non-specific background signal. Activated platelets were assessed 
as the percentage of platelets with positive activation-dependent platelet surface marker 
PAC-1 FITC in CD61 positive cells gate. Results were obtained as a measurement in tripli-
cate and tested with paired Student’s t-test for significance. To confirm the concentration 
level of flavanone which caused statistically significant inhibition of platelet activation, 
measurements were repeated on five independent samples in triplicate.
Statistical analysis
The antiaggregatory effect of flavanone and inhibitor drugs were assessed with one-
way ANOVA test with post hoc Tukey analysis for multiple comparison. For comparison of 
RM and logP linear regression analysis was performed. Paired Student’s t-test was used for 
the estimation of MINaAC and platelet activation inhibition measured by flow cytometry. 




To assess the lipophilicity of flavonoids reverse-phase thin-layer chromatography was 
conducted on a series of 20 compounds. Chromatographic parameter, RM, the surrogate of 
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Flavones            
Flavoneb 0.3892 3.815 2.97 3.56 3.74 2.55 3.56 3.46 2.27 4.04 3.18
6-Hydroxyflavonec –0.0378 0.954 2.66 3.72 3.23 2.28 3.62 3.17 1.66 3.52 2.85
7-Hydroxyflavonec –0.0884 15.259 2.66 3.32 3.23 2.22 3.62 3.17 1.66 3.52 2.84
Tangeretind 0.4202 30.518 2.18 2.66 3.78 3.71 3.04 3.5 0.63 4.21 3.02
Tectchrysinee 0.5202 0.954 3.16 3.13 3.48 2.88 3.85 3.17 1.33 3.52 2.95
Chrysine dimethyl ethere 0.5202 1.907 3.01 3.27 3.75 2.95 3.62 3.48 1.57 4.04 3.13
Chrysineb 0.0126 3.815 3.01 2.88 2.94 2.27 3.52 2.87 1.08 3.02 2.55
Acacetind 0.0378 3.815 2.85 3.15 3.00 2.56 3.35 2.88 0.77 3.03 2.52
Diosmetine –0.3590 7.629 2.55 3.10 2.28 2.47 3.1 2.59 0.22 2.55 2.19
Apigeninb –0.3892 3.815 2.71 2.10 2.46 1.89 3.02 2.58 0.52 2.52 2.11
Luteoline –0.5942 7.629 2.40 2.40 1.97 1.86 2.53 2.28 -0.03 2.03 1.73
Flavonols
3,6-Dihydroxyflavonec –0.0378 0.119 2.42 3.64 2.94 1.97 3.05 2.87 1.08 3.02 2.4
3,7-Dihydroxyflavonec –0.0631 1.907 2.42 3.27 2.94 2.01 3.05 2.87 1.08 3.02 2.4
Galanginb 0.0000 122.070 2.76 2.83 2.65 2.08 2.25 2.58 0.52 2.52 1.99
Rhamnetind –0.2083 0.954 2.30 2.58 2.22 2.23 1.87 2.29 –0.31 2.06 1.63
Isorhamnetind –0.3203 7.629 2.30 1.76 1.99 2.35 1.87 2.29 –0.31 2.06 1.65
Quercetinb,f –0.5863 15.259 2.77 2.07 1.68 1.63 1.54 1.99 –0.56 1.54 1.23
Flavanons
Pinocembrin-7-methylethere 0.3100 0.954 3.28 4.11 3.13 2.75 3.20 2.78 1.52 3.06 2.66
Pinocembrine –0.1076 15.259 3.14 3.93 2.60 2.11 2.88 2.48 1.27 2.55 2.26
Hesperetinb –0.4536 1.907 2.68 2.90 1.94 2.24 2.60 2.19 0.41 2.08 1.91
Flavanoneb 0.1811 0.062 3.10 3.62 3.18 2.41 3.14 3.07 2.47 3.57 2.93
a MINaAC represents minimal antiaggregatory concentration (taken from reference 17).
Flavonoids purchased from: b Merck KgaA, Germany, c ChromaDex, USA, d BioChemika, Switzerland, e Extrasyn-
these, France.
f In the form of quercetin dihydrate.
logP, was in the range from –0.59 to 0.52. The highest RM values were obtained for tec-
tochrysin and chrysin dimethyl ether, and the lowest for luteolin (Table I). 
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Computational values of logP determined in Chem Axon were in the range of 2.18 to 
3.28 with the highest value for pinocembrin-7-methylether. The same compound had the 
highest value of ChemSketch calculated logP (4.11). In the case of Molinspiration calcu-
lated logP, the most lipophilic flavonoids were flavone (3.74), tangeretin (3.78) and tech-
tochrysin (3.48). SwissADME calculates logP according to five different algorithms and 
expresses their consensus logP value. These values were the highest for flavone (3.18), 
tangeretin (3.02) and chrysin dimethyl ether (3.13) which is in accordance with experimen-
tally determined RM values.
Results of linear regression (Table II) for multiple logP and RM showed strong positive 
correlation R = 0.8631 and R = 0.9283 (p < 0.001) for calculated SwissADME consensus logP 
and Molinspiration program, resp. ChemSketch and Chemicalize logP showed moderate 
positive correlation to chromatographic parameter RM R = 0.5454 (p = 0.009) and R = 0.4448 
(p = 0.0434).
Based on the strong positive correlation between RM parameter and logP calculated 
by Molinspiration and SwissADME application and moderate positive correlation with 
ChemSketch and Chemicalize logP, it can be concluded that chromatographic parameter 
RM is a good surrogate of logP and a good predictor of flavonoid lipophilicity. 
This approach was also previously used as a part of QSAR study of flavonoids as bac-
teriostatic agents against Escherichia coli, with the conclusion that high correlation between 
calculated logP (ClogP) values and predicted MIC50 implies that hydrophobicity plays a 
major role in the antibacterial activity of flavonoids by their interaction with membranes (21). 
When inhibition of Syk protein tyrosine kinase activity and human mast cells degranulation 
was studied on a set of flavonoids, a significant relationship was observed between com-
pound logP and the observed inhibitory effect (22). LogP was also included in global models 
for the evaluation of toxicity of flavonoid compounds in the metabolic environment of mam-
mals (23). As a measure of lipophilicity, logP offers a very convenient way of predicting the 
possible extent of flavonoid action in vivo based on their interaction with biomembranes.
Relationship between inhibition of platelet aggregation and lipophilicity of flavonoids
For flavonoids listed in Table I previously tested in platelet aggregation assay induced 
by ADP (17), MINaAC values were correlated with calculated logP (Table III).
Table II. Results of regression analysis for chromatographic parameter RM and logP for flavonoids from Table I
Application Adjusted R2 Multiple R p-value
logP_ChemAxon 0.1556 0.4448 0.0434
logP_ChemSketch 0.2605 0.5454 0.009
logP_Molinspiration 0.8545 0.9283 <0.001
Swiss_ilogP 0.5649 0.7659 <0.001
Swiss_xlogP3 0.4011 0.6566 0.0012
Swiss_wlogP 0.7269 0.8605 <0.001
Swiss_mlogP 0.4678 0.7032 <0.001
Swiss_silicos-it 0.7530 0.8748 <0.001
Swiss_consensuslogP 0.7315 0.8631 <0.001
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Table III. Correlations for logP and minimal antiaggregatory concentration (MINaAC) of flavonoids





logP_ChemAxon –0.7576a 0.6691 0.1599 –0.0103 –0.5922a 0.0724
logP_ChemSketch –0.2667 0.0082 0.3013 –0.1214 –0.2005 –0.1545
logP_Molinspiration 0.1908 0.1341 –0.2218 –0.0597 0.1498 –0.0047
Swiss_ilogP 0.5384 0.0062 –0.6678 –0.0279 0.4078 –0.1949
Swiss_xlogP3 –0.3550 –0.1014 –0.2666 –0.3042 –0.2297 –0.2414
Swiss_wlogP 0.2406 0.0428 –0.3616 –0.1106 0.1785 –0.0545
Swiss_mlogP –0.2522 0.0983 –0.2195 –0.1419 –0.2668 –0.1333
Swiss_silicos-it 0.2836 0.0303 –0.3728 –0.1070 0.1996 –0.1066
Swiss_consensuslogP 0.1157 0.0185 –0.3645 –0.1628 0.0542 –0.1611
a Statistically significant correlation (p < 0.05).
The relationship was tested on a whole set of flavonoids, as well as individual classes 
of flavonoids and their combinations (flavones, flavonols, flavanones, flavones and flavo-
nols, flavones and flavanones, flavonols and flavanones). Statistically significant correla-
tion was found between MINaAC and logP calculated by Chemicalize application: strong 
negative correlation R = –0.7576 (p = 0.0069) for flavone group and moderate negative cor-
relation R = –0.5922 (p = 0.0200), for combined groups of flavone and flavanone. Van Dijk et 
al. (24) found that flavonols exhibited a substantially higher affinity for liposomes than 
flavanones attributing this result with a far more planar configuration of the flavonols in 
comparison with the tilted configuration of flavanones. Oteiza et al. (10) proposed lipophi-
licity of flavonoid molecule as a basis for flavonoid interactions with biomembranes as well 
as interactions of polyphenols at the surface of bilayers through hydrogen bonding that 
can act to reduce the access of deleterious molecules, thus protecting the structure and 
function of membranes. Results of the study by Arora et al. (25) on the modulation of mem-
brane fluidity by flavonoids suggest that partition into the hydrophobic core causes a dra-
matic decrease in lipid fluidity of the membrane.
Our results are in concordance with the assumption that flavonoids have a tendency 
to localize in the membrane bilayer based on their lipophilicity. In that sense, flavonoids 
with higher lipophilicity have greater potency to interact with the membrane and conse-
quently cause inhibition of platelet aggregation at a lower concentration, presumably by 
causing a decrease in lipid fluidity. Thus, the stabilized platelet membrane is less suscep-
tible to the inducers of platelet aggregation. This is in accordance with high negative cor-
relation observed between values of logP calculated by Chemicalize application with  MINaAC 
values; flavonoids with higher values of logP have lower values of MINaAC and stronger 
antiplatelet effect.
When average values of logP (Chemaxon) for different classes of flavonoids were cal-
culated (based on data in Table I), the following trend was observed: flavanones (2.50), 
flavonols (2.76), flavones (3.05). The same trend was observed when comparing antiaggre-
gatory effect; the higher lipophilicity is, the more prone antiaggregatory effect is, i.e., MINaAC 
are lower: flavanons (24.66 μmol L–1), flavonols (7.75 μmol L–1), flavones (4.55 μmol L–1). 
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Although this observation confirms objective of our work, it should be noted that not all 
classes of flavonoids were equally represented in our study (flavanones, n = 4, flavonols, 
n = 6, flavones, n = 11).
Influence of flavonoids and antiplatelet drugs combinations on primary hemostasis
When compared to our previous study, an antiaggregatory activity which was evalu-
ated on a set of 30 flavonoids in the platelet-aggregation assay induced by ADP (17), flava-
none showed much higher potency with MINaAC concentration in the nanomolar range 
(63 nmol L–1). As this was the lowest MINaAC that we have observed among all flavonoids 
present in our library of compounds, further studies were conducted using different com-
mercially available inducers of platelet aggregation for impedance aggregometry, namely 
TRAP-6, collagen, ristocetin and arachidonic acid (Table IV).
Table IV. Effects of flavanone on platelet aggregation depending on the agonist used  
in impedance aggregation assay






AA – arachidonic acid, ADP – adenosine diphosphate, MINaAC – 
minimal antiaggregatory concentration, TRAP-6 – thrombin recep-
tor-activating peptide (hexapeptide)
In the herein presented study, MINaAC of 0.063 μmol L–1 was observed when a weak 
agonist ADP was used to induce aggregation. When TRAP-6, hexapeptide surrogate of 
thrombin, was used as an inducer of platelet aggregation MINaAC of 2 μmol L–1 was ob-
tained. Similarly, stronger inducers of platelet aggregation required more flavanone to ob-
serve a statistically significant decrease of platelet, i.e., MINaAC was 0.5 μmol L–1 in platelet 
aggregation assays induced by collagen, ristocetin and AA.
Experiments on the combined inhibitory effect of flavanone and known inhibitors of 
platelet aggregation were designed on Multiplate® analyzer to assess their interactions and, 
to some extent, indicate a possible mechanism of flavanone action in the presence of strong 
or weak agonist. A PLC inhibitor U73122, calcium channels blocker verapamil and cyclooxy-
genase inhibitor indomethacin were used for this purpose. Each experiment included the 
determination of platelet aggregation of either flavanone or the inhibitor (known antiplatelet 
drug), or the combination of flavonoid and inhibitor. Platelet aggregation assays in this in-
stance were induced by a strong (TRAP-6) or a weak (ADP) agonist of aggregation. To assess 
the statistical significance of different treatments one-way ANOVA with post hoc test was used 
for results assessment. The results of these analyses are shown in Fig. 1.
The statistically significant difference between treated samples was observed for the 
combination of U73122, an inhibitor of PLC, and flavanone, for both (TRAP-6, ADP) agonist 
applied (Fig. 1a). As expected, flavanone standard reduced platelet aggregation by 14 %, 
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U73122 reduced platelet aggregation by 25 % while the combination of the two reduced plate-
let aggregation by 35 % in TRAP-6 induced platelet assay. However, the combined effect of 
flavanone and U73122 on platelet aggregation induced by ADP was a reduction of 50 %. Sig-
nificant combined inhibitory effect of flavanone and U73122 on the first and most important 
enzyme in platelet activation cascade, even in the presence of a strong agonist, could be the 
consequence of specific inhibition of PLC-mediated signaling pathways upstream of PLC. As 
membrane fluidity is involved in the regulation of platelet activation, i.e., change of cell shape, 
pseudopodia formation and exposition of receptors that stimulate platelet aggregation (26, 
27), our assumption is that flavonoids as lipophilic substances influence membrane fluidity 
by increasing membrane rigidity thus reducing the exposition of receptors at the membrane 
surface and subsequent activation of platelet aggregation signaling pathways. Experiments 
on G protein-coupled receptor show that increased membrane fluidity stimulates an active 
form of the receptor (28). Flavanone can interact in a non-specific way with platelet mem-
brane, and, thus, interfere in signal transduction of G-coupled proteins to PLC.
When combined with verapamil, flavanone showed a reduction of platelet aggregation 
induced by TRAP-6 (Fig. 1b). However, this effect was not observed when ADP was used as 
platelet aggregation inducer. As both pathways induced by ADP and TRAP-6 include calcium 
liberation from dense tubules it could be assumed that this is not a common target (29). 
Rather, upstream signaling pathways unique to TRAP-6 such as Rho/Rho-kinase could be 
possible targets of flavanone (29). The absence of combined inhibitory influence of flavanone 
and indomethacin regardless of the used agonist (Fig. 1c), indicates that the antiaggregatory 
effect of flavanone is not achieved downstream of cyclooxygenase 1.
Fig. 1. Results of impedance aggregometry assays induced by a strong (TRAP-6) and a weak (ADP) 
agonist of aggregation for: a) flavanone and a phospholipase C inhibitor U73122, b) calcium channels 
blocker verapamil and c) cyclooxygenase inhibitor indomethacin, and flavanone and inhibitor drug 
combinations. Asterisks indicate statistical significance.
a)                                                                            b)
                                           c)
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Although the methodology used in these experiments lacks sensitivity to pinpoint 
precise target of flavanone, results obtained are in accordance with the presumption of the 
non-specific mechanism of platelet aggregation through the interaction with the mem-
brane rigidity.
Flow cytometry
If flavanone influences membrane rigidity, expression of receptors on platelet surface 
will be reduced, e.g., by inhibiting transverse diffusion also known as flip-flop. To assess the 
expression of receptors in the presence and the absence of flavonoid, flow cytometry was 
used. Platelet activation trough modulation of inside-out signaling of integrin αIIbβ3 is sig-
nificantly inhibited by flavanone (Figs. 2 and 3). 
The observed effect is dose-dependent (R = 0.9897, p < 0.05, Fig. 2). An example of flow 
cytometry results is shown in Fig. 3: statistically significant reduction in the receptor exposi-
tion is achieved at higher concentrations of flavanone (488 μmol L–1) when compared to the 
untreated samples of the same participant (p = 0.0031). This result was confirmed subse-
quently by the analysis of five independent blood samples (p = 0.0018).
Fig. 2. Inhibitory effect of flavanone on platelet aggregation induced by TRAP-6 on platelet-rich plasma.
Fig. 3. Flow cytometry analysis of platelet activation induced by TRAP-6 in: a) absence and b) the 
presence of flavanone. Mean fluorescence intensity is measured using integrin αIIbβ3 antibody.
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Despite the noticeable effect, when compared with MINaAC observed in impedance 
aggregometry, only a rather high concentration of flavanone achieved significant inhibition 
of platelet activation in flow cytometry experiments. This could be due to the difference in 
the type of samples (impedance aggregometry uses whole blood while platelet-rich plasma 
is used for flow cytometry experiments), as well as experimental set up (concentration, sam-
ple manipulation, time, etc.). This is in accordance with the results of Ostertag et al. (30) and 
Vaiyapuri et al. (31) who also used higher concentrations of phenolic compounds to see mea-
surable results in flow cytometry experiments. Although they present complementary meth-
ods, flow cytometry and impedance aggregometry comprise different aspects of platelet 
function and are therefore not interchangeable when agonist-induced platelet reactivity is 
assessed (32). As for methodology, impedance aggregometry, by performing in whole blood, 
enables other blood elements to influence platelet aggregation, therewith, functions under 
more physiological conditions (33).
CONCLUSIONS
In platelet aggregation assays induced by ADP, all flavonoids showed antiaggregatory 
activity (17), suggesting a non-specific mechanism of action related to their lipophilicity and 
stabilization of platelet membrane. Lipophilicity analysis showed a highly negative correla-
tion between logP and MINaAC for groups of flavones and flavanones confirming the objec-
tive of our study. If so, the exposition of receptors necessary for the promotion of platelet 
activation and primary clot formation should be diminished. This was confirmed by flow 
cytometry in which lowered expression of the activated form of integrin αIIbβ3 was ob-
served in the presence of flavanone. Platelet membrane stabilization by flavonoids as a 
mechanism of antiaggregatory effect has been supported by impedance aggregometry ex-
periments when specific inhibitors of platelet aggregation signaling pathways were used in 
the presence of a weak and strong agonist of aggregation. While individual flavonoid can 
have specific targets within aggregation signaling pathways, flavonoids share a common 
non-specific mechanism of platelet aggregation inhibition related to their lipophilicity and 
membrane stabilization that, to some extent, contributes to their antiaggregatory effect.
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Acronyms, abbreviations, symbols. – AA – arachidonic acid, ADP – adenosine diphosphate, CD – 
cluster of differentiation, ClogP – calculated logP, FITC – fluorescein isothiocyanate, Ig – immuno-
globulin, logP – logarithm of partition coefficient, MINaAC – minimal antiaggregatory concentration, 
PAC-1 – anti-integrin αIIbβ3 antibody, PE – phycoerythrin, PLC – phospholipase C, PRP – platelet-
rich plasma, RM – chromatographic parameter, surrogate measurement of lipophilicity, TRAP-6 – 
thrombin receptor-activating peptide (hexapeptide).
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